
Rituximab and eculizumab for delayed haemolytic transfusion reactions: low-quality evidence, but a life‑threatening scenario
In a recent commissioning policy, NHS England has commissioned eculizumab and rituximab for the management of delayed haemolytic transfusion reactions (DHTR) and hyperhaemolysis (HH), and rituximab […]